Sanofi Venetoclax: Breakthrough NK Cell Therapy Stuns at ASH 2023
Innate Pharma SA, in collaboration with Sanofi, shared updated efficacy and safety results from a Phase 1/2 dose-escalation study...
Merck, Eisai’s Shock: KEYTRUDA-LENVIMA Fail
Merck and Eisai have reported that the Phase 3 LEAP-001 trial for the first-line treatment of patients with advanced...
Pfizer Unveils Marstacimab: Hemophilia’s New Hope
Pfizer Inc. has shared promising results from its pivotal Phase 3 BASIS clinical trial of marstacimab, a potential new...
myTomorrows Unveils New Patient Engagement Tactics with AI
Today we delve into the dynamic world of clinical trials. This discussion aims to uncover the intricacies and challenges...
Merck Evobrutinib Fails in Trials: A Devastating Outcome for MS
Merck KGaA, a renowned science and technology company, has announced the results of its two Phase III EVOLUTION clinical...
BMS Opdivo Wins FDA Fast-Track: Remarkable Cancer Hope
Bristol Myers Squibb (BMS) has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review...
Unlock Hidden Insights: Data Management Revolutionizes Clinical Trials
In today’s in-depth conversation, we delve into the evolving landscape of data management through EHR in clinical trials, focusing...
Expert Advice: Navigating Clinical Trial Sites in the Digital Era
The Society for Clinical Research Sites (SCRS) European Site Solutions Summit 2023 served as a pivotal gathering for clinical...
Pfizer New Diet Drug: Obsession for Healthy Change
Pfizer Inc., a renowned pharmaceutical company, has recently shared encouraging topline outcomes from their Phase 2b clinical trial. This...
PsychoGenics Revolutionary Brain Drug Set to Combat Mental Ills
PsychoGenics Inc., with its drug discovery platform PGI Drug Discovery LLC, has announced an exclusive license agreement with Roche...
